 Potential first-in-class therapy for a subset of gastric and gastroesophageal GEJ cancers that overexpress fibroblast growth factor receptor 2 FGFR2b Potential first-in-class therapy for a subset of gastric and gastroesophageal GEJ cancers that overexpress fibroblast growth factor receptor 2 FGFR2b 